Supporting publications

Supporting publications

(Please hover over the paper reference and click for link to the paper on the publisher website)

Discovery paper and clinical study - Glyoxalase 1 inducer formulation (now called GlucoRegulate)

Mingzhan Xue, Martin O. Weickert, Sheharyar Qureshi, Ngianga-Bakwin Kandala, Attia Anwar, Molly Waldron, Alaa Shafie, David Messenger, Mark Fowler, Gail Jenkins, Naila Rabbani, and Paul J. Thornalley. Improved Glycemic Control and Vascular Function in Overweight and Obese Subjects by Glyoxalase 1 Inducer Formulation. Diabetes 2016;65:2282–2294 | DOI: 10.2337/db16-0153

Further analysis of the clinical study

Naila Rabbani, Mingzhan Xue, Martin O. Weickert and Paul J. Thornalley. Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination—Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation. Nutrients 2021, 13, 2374. https://doi.org/10.3390/nu13072374

Glo1 inducer (GlucoRegulate) corrects high glucose concentration induced glycolytic overload

Irshad, Z., Xue, M., Ashour, A., Larkin, J.R., Thornalley, P.J. and Rabbani, N. (2019) Activation of the unfolded protein response of endothelial cells in high glucose by methylglyoxal. Scientific Reports 9, 7889.

Glo1 inducer (GlucoRegulate) counters high glucose concentration induced inflammation by preventing activation of the unfolded protein response

Xue, M., Rabbani, N. and Thornalley, P.J. (2024) Increased cellular protein modification by methylglyoxal activates three sensors of the unfolded protein response. Redox Biol. 65, 103025.

Glycolytic overload contributes to the development of insulin resistance, beta-cell glucotoxicity, type 2 diabetes development and vascular complications of diabetes and is countered by Glo1 inducer (GlucoRegulate)

Rabbani, N. and Thornalley, P.J. (2024) Hexokinase-linked glycolytic overload and unscheduled glycolysis in hyperglycemia-induced pathogenesis in insulin resistance, beta-cell glucotoxicity and diabetic vascular complications. Frontiers in Endocrinology 14, 1268303

Glycolytic overload contributes to impairment of the incretin effect in obesity and type 2 diabetes and is likely countered by GlucoRegulate (for improved appetite control)

Rabbani, N. and Thornalley, P.J. (2024) Unraveling the impaired incretin effect in obesity and type 2 diabetes: key role of hyperglycemia-induced unscheduled glycolysis and glycolytic overload. Diabetes Res. Clin. Pract., 217, 111905

GlucoRegulate provides a new option for improved metabolic health, liver health and support for healthy ageing

Xue, M., Rabbani, N. and Thornalley, P.J. (2025) Glyoxalase 1 inducer, trans-resveratrol and hesperetin – dietary supplement with multi-modal health benefits. Antioxidants 14, 956.

GlucoRegulate provides a new option for improved liver health

Rabbani, N. and Thornalley, P.J. (2025) Molecular mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD): functional analysis of glucose and fructose metabolism pathways. Clinical Science 139, 1406 – 1429.

GlucoRegulate likely provides a new option for supporting brain health

Alhujaily, M., Rabbani, N. and Thornalley, P.J. (2026) Hexokinase-2–glycolytic overload axis in brain disorders exacerbated by diabetes. Trends in Endocrinology and Metabolism, https://doi.org/10.1016/j.tem.2026.09.006